I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Carotid endarterectomy (CEA) is an effective surgical procedure to reduce the risk of stroke in symptomatic patients with severe stenosis of the internal carotid artery.\[[@ref1][@ref2]\] Myocardial injury after noncardiac surgery is common\[[@ref3]\] and often associated with adverse cardiac events and mortality, both in the short- and long-term.\[[@ref4][@ref5]\] A recent study reported that the incidence of myocardial injury (cardiac troponin I \[cTnI\] \> 0.04 ng/ml) shortly after CEA was as high as 42.5%,\[[@ref6]\] but there are few methods to reduce postoperative myocardial injury. Walsh *et al.*\[[@ref7]\] introduced remote ischemic preconditioning during CEA to reduce myocardial injury, but the sample size in their study was very small, and the procedure was very time-consuming. Sevoflurane exhibits cardioprotective effects during cardiac surgery\[[@ref8]\] and improves clinical as well as biochemical parameters during coronary artery bypass surgery.\[[@ref9][@ref10]\] Moreover, sevoflurane significantly reduces the number of cardiac complications in CEA,\[[@ref11]\] although the associated vasodilation may cause cerebral steal and thus cerebral ischemia.\[[@ref12]\] However, sevoflurane dilates cerebral vessels in a concentration-dependent manner, such that low-dose sevoflurane induces only mild vasodilation.\[[@ref13]\] In humans, sevoflurane at an end-tidal concentration of 0.5--1 vol% provides endothelial protection against ischemia/reperfusion injury.\[[@ref14]\] Based on these previous findings, we carried out a randomized controlled study to test the hypothesis that low-dose sevoflurane along with propofol decreases the incidence of myocardial injury in patients undergoing CEA.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

The study was conducted at Xuan Wu Hospital, Capital Medical University, China, between November 2011 and December 2013. The inclusion criteria were: Symptomatic patients with severe atherosclerotic stenosis in the carotid artery (≥70% of the luminal diameter diagnosed by Color Doppler) and a normal preoperative cTnI value (≤0.04 ng/ml). Patients were excluded if they had a history of acute myocardial infarction within 3 months, angina pectoris within 1-month, stroke within 6 months, CEA and other surgical procedures in progress simultaneously, obvious liver and renal dysfunction, hemoglobin \<90 g/L, fasting blood glucose \>7.0 mmol/L, and/or hypertension with blood pressure \>180/110 mmHg. Patients enrolled in the study were allocated randomly to Group A (propofol alone) or Group B (0.8% end-tidal sevoflurane combined with propofol) the day before surgery. Randomization was based on a computer-generated randomization list, and the random number was sealed in an envelope until it was delivered to the patient. Patients, laboratory personnel, statisticians, and outcome assessors were blinded to the allocation. The study was approved by the ethics committee of our hospital. All patients provided written informed consent before entering the study.

Perioperative management {#sec2-1}
------------------------

Patients were managed according to standard protocols by the same neurosurgical and anesthesia teams. All patients were required to fast for 8 h before the operation and were premedicated with intramuscular injections of atropine (0.01 mg/kg) and phenobarbital sodium (2 mg/kg) 30 min before the induction of anesthesia. Medications for comorbidities were continued until the morning of surgery. Anesthetic monitors (five-lead electrocardiogram, pulse oximetry, noninvasive blood pressure, and temperature) were used for all patients. In each patient, the blood-pressure cuff was placed on the arm that had a higher blood pressure. If the blood pressure in the two arms was the same, the cuff was placed on the right arm. Blood pressure was measured continuously throughout surgery. A pulsed Transcranial Doppler (TCD) transducer (EMS-9PB, Delica Electronics, Shenzhen, China) was placed over the temporal bone to measure the middle cerebral artery velocity. Anesthesia was induced with etomidate (0.3 mg/kg), fentanyl (0.03 mg/kg), and rocuronium (0.6 mg/kg) through an intravenous (i.v.) line in the patient\'s hand, forearm, or arm. For anesthetic maintenance, patients in Group A received i.v. propofol (3--5 mg·kg^−1^·h^−1^) and remifentanil (0.1--0.15 μg·kg^−1^·min^−1^), and patients in Group B received 0.8% end-tidal sevoflurane, propofol (2--5 mg·kg^−1^·h^−1^), and remifentanil (0.1--0.15 μg·kg^−1^·min^−1^). The speed of propofol infusion was adjusted to maintain the bispectral index at 40--60. The following drugs were given to maintain stable hemodynamics during surgery: Phenylephrine, 25--50 μg i.v. for changes in mean arterial pressure (MAP) \>30% compared to the ward baseline value; urapidil, 5--10 mg i.v. for changes in MAP \>30% above the ward baseline value; esmolol, 20--40 mg i.v. for a heart rate \>100 beats per minute (bpm); and atropine, 0.25--0.5 mg i.v. for a heart rate \<50 bpm. Volume-controlled ventilation and respiratory frequency were adjusted to achieve a tidal volume of 8--10 ml/kg body weight and an intraoperative end-tidal carbon dioxide tension of 35--45 mmHg. At the end of surgery, all anesthetics were stopped. The tracheal tube was removed when spontaneous respiration returned, and the bispectral index exceeded 80. All patients were transferred to the neurosurgical ward, and five-lead electrocardiogram, blood pressure, heart rate, and pulse oximetry were continuously monitored for 24 h. TCD monitoring was used at intervals. For all patients, i.v. patient-controlled analgesia was provided using fentanyl and ondansetron. Adverse cardiac events were diagnosed by a cardiologist during the patient\'s hospitalization. Patient data were obtained from the hospital information system.

Study end points {#sec2-2}
----------------

The primary end-point was the rate of myocardial injury, as measured by cTnI. In the healthy population, the 99 percentile value of cTnI is 0.04 ng/ml;\[[@ref15]\] thus, the myocardial injury was defined as a cTnI \> 0.04 ng/ml.\[[@ref6]\] Blood samples (3 ml) were taken from the peripheral vein before anesthesia and at 4, 24, and 72 h after surgery. This protocol was similar to the one used in a previous study.\[[@ref16]\] Samples were immediately centrifuged at 3000 r/min for 10 min, and the serum layer was aspirated and stored at −70°C until analysis. Serum cTnI concentrations were measured using an AxSYM troponin I analyzer (Abbott Laboratories, Longford, Ireland). The lower limit of detection was 0.02 ng/ml. The assays were performed by a technician who was blinded to the clinical data. Myocardial infarction was diagnosed if the cTnI value exceeded 1.5 ng/ml and myocardial ischemia if the cTnI value was between 0.5 ng/ml and 1.5 ng/ml.\[[@ref17]\]

The secondary outcome was hemodynamic stability, which was determined by measuring blood pressure and heart rate before clamping, 10 min after clamping, and 10 min after declamping. Resting blood pressure and heart rate were measured at 4, 24, 48, and 72 h after surgery. Doses of vasoactive drugs administered intraoperatively and during the first 3 postoperative days were recorded.

We also compared the adverse cardiac events, including acute coronary syndrome (ACS), myocardial infarction, heart failure, and new-onset arrhythmia, during the patients' hospital stay after surgery. ACS was defined as resting angina, new-onset angina, and progressive angina with ST-segment depression or T-wave inversion. The incidence of severe neurological complications, such as stroke and cerebral hyperperfusion syndrome, was recorded as well.

Statistical analysis {#sec2-3}
--------------------

The primary end-point was the rate of positive cTnI within the first 3 days after surgery. A previous study reported that the rate of myocardial injury was 42.5% in patients with propofol anesthesia after CEA.\[[@ref6]\] Our pilot study in 20 patients administered 0.8% end-tidal sevoflurane combined with propofol showed that the rate of positive cTnI was 15%. With the (two-sided) α error set at 0.05 and the β error set at 0.1 (power of 90%), 54 patients per group were needed. Considering a 10% discontinuation rate, we recruited 60 patients per group.

Normally distributed data are presented as mean ± standard deviation. Means were compared using a one-way analysis of variance (ANOVA). Categorical variables are expressed as percentages. Proportions were compared using the fourfold table *χ*^2^ test. In all cases, a two-tailed *P* \< 0.05 was considered statistically significant. All analyses were performed using SPSS software version 11.0 (SPSS Inc., Chicago, IL, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

From November 2011 to December 2013, 126 patients were randomly assigned to Group A (*n* = 65) or Group B (*n* = 61). Of these, 122 patients completed the study \[[Figure 1](#F1){ref-type="fig"}\].

![Patient allocation.](CMJ-128-1862-g001){#F1}

Baseline characteristics of the patients {#sec2-4}
----------------------------------------

[Table 1](#T1){ref-type="table"} shows the baseline characteristics and demographic data of the patients. Baseline characteristics were balanced between the two treatment groups. Coronary artery disease was predefined as a history of myocardial infarction or coronary revascularization, or a \>50% stenosis on coronary angiography, or myocardial ischemic induced by radionuclide or echocardiographic stress testing.\[[@ref18]\]

###### 

Baseline characteristics

  Items                              Group A (*n* = 62)   Group B (*n* = 60)   *P*
  ---------------------------------- -------------------- -------------------- -------
  Age (years)                        65.8 ± 5.9           66.7 ± 6.4           0.410
  Males, *n* (%)                     54 (87.1)            56 (93.3)            0.248
  BMI (kg/m^2^)                      24.0 ± 3.0           24.1 ± 2.7           0.783
  Smoking habit, *n* (%)             32 (51.6)            29 (48.3)            0.717
  Hyperlipidemia, *n* (%)            10 (16.1)            10 (16.7)            0.936
  Diabetes mellitus, *n* (%)         18 (29.0)            14 (23.3)            0.474
  Cerebral ischemia, *n* (%)         39 (62.9)            37 (61.7)            0.888
  Hypertension, *n* (%)              40 (64.5)            42 (70.0)            0.519
  Coronary artery disease, *n* (%)   10 (16.1)            12 (20.0)            0.578
  STsegment depression, *n* (%)      20 (32.3)            22 (36.7)            0.608
  Duration of operation (min)        196.1 ± 52.9         205.2 ± 94.3         0.515
  Infusion volume (ml)               1622.6 ± 371.7       1665.0 ± 348.3       0.517
  Amount of bleeding (ml)            57.6 ± 23.7          54.4 ± 24.9          0.474
  Urinary volume (ml)                508.1 ± 229.8        510.3 ± 237.3        0.957
  Fentanyl (mg)                      0.3 ± 0.1            0.3 ± 0.1            0.754
  Remifentanil (mg)                  1.6 ± 0.3            1.5 ± 0.4            0.222

Data are reported as mean ± SD unless otherwise indicated. BMI: Body mass index; SD: Standard deviation.

Cardiac troponin I outcomes {#sec2-5}
---------------------------

The cTnI values of all the patients were within the normal range (≤0.04 ng/ml) before surgery. During the first 3 postoperative days, 25 patients had a peak cTnI value \>0.04 ng/ml, 18 (29.0%) from Group A and 7 (11.7%) from Group B; this result was statistically significant (*P* = 0.018). Most cTnI values (17/25) reached a peak on the 1^st^ postoperative day, without a significant difference between the two groups (12/62 vs. 5/60, *P* = 0.079). Nine patients (14.5%) in Group A and 3 (5%) patients in Group B had peak cTnI values \>0.5 ng/ml (*P* = 0.078). In all patients, the cTnI values were below the diagnostic cut-off for myocardial infarction (1.5 ng/ml; [Figure 2](#F2){ref-type="fig"}).

![Peak cardiac troponin I (cTnI) value of patients who suffered myocardial injury (cTnI \> 0.04 ng/ml) during the first 3 days after surgery.](CMJ-128-1862-g002){#F2}

The incidence of myocardial injury (cTnI \>0.04 ng/ml) was compared in patients with a history of hypertension, coronary artery disease, ST-segment depression (\>1 mm), cerebral ischemia, hyperlipidemia, or diabetes mellitus. In patients with hypertension, 14 (35.0%) in Group A and 6 (14.3%) in Group B had a peak cTnI value \>0.04 ng/ml, *P* = 0.029. In patients with coronary artery disease, eight patients (80.0%) in Group A and four patients (33.3%) in Group B suffered myocardial injury (*P* = 0.043). In patients with ST-segment depression, 13 (65.0%) in Group A and 5 (22.7%) in Group B had a cTnI \>0.04 ng/ml (*P* = 0.006). In patients with cerebral ischemia, 15 (38.5%) in Group A and 4 (10.8%) in Group B had a peak cTnI value \>0.04 ng/ml (*P* = 0.016; [Table 2](#T2){ref-type="table"}).

###### 

Incidence of myocardial injury in patients with comorbidities

  Comorbidities             Group A   Group B     *P*              
  ------------------------- --------- ----------- ----- ---------- ---------
  Hypertension              40        14 (35.0)   42    6 (14.3)   0.029\*
  Coronary artery disease   10        8 (80.0)    12    4 (33.3)   0.043\*
  ST-segment depression     20        13 (65.0)   22    5 (22.7)   0.006\*
  Cerebral ischemia         39        15 (38.5)   37    4 (10.8)   0.016\*
  Hyperlipidemia            10        6 (60)      10    4 (40)     0.656
  Diabetes mellitus         18        9 (50)      14    7 (50)     1.000

\*Significant at *P*\<0.05. cTnI: Cardiac troponin I.

Hemodynamic stability {#sec2-6}
---------------------

There were no significant differences in any of the hemodynamic parameters either within or between Groups A and B \[[Table 3](#T3){ref-type="table"}\].

###### 

Hemodynamic parameters

  Items        Before clamping   10 min after clamping   10 min after declamping   4 h after operation   24 h         48 h         72 h         *P*
  ------------ ----------------- ----------------------- ------------------------- --------------------- ------------ ------------ ------------ -------
  HR (bpm)                                                                                                                                      
   Group A     67.2 ± 8.4        68.0 ± 9.3              68.5 ± 8.5                68.6 ± 7.3            70.3 ± 7.8   70.5 ± 7.6   71.0 ± 7.6   0.068
   Group B     67.0 ± 10.0       68.6 ± 11.0             68.0 ± 11.0               68.7 ± 9.3            69.1 ± 9.6   69.6 ± 8.9   71.4 ± 7.9   0.298
  MAP (mmHg)                                                                                                                                    
   Group A     83.3 ± 8.6        83.7 ± 9.3              81.0 ± 7.2                82.3 ± 5.9            84.1 ± 5.9   83.9 ± 6.2   83.6 ± 7.8   0.228
   Group B     83.6 ± 9.2        83.2 ± 8.3              81.3 ± 8.4                84.3 ± 8.2            84.2 ± 6.2   84.0 ± 6.0   81.3 ± 7.8   0.132

Data are reported as mean ± SD. HR: Heart rate; MAP: Mean arterial pressure; SD: Standard deviation.

The percentage of patients who required atropine, esmolol, phenylephrine, or urapidil during the operation and the first 3 days postoperatively was not significantly different between the two groups (4.8% vs. 1.7%, 38.7% vs. 28.3%, 86.7% vs. 81.7%, and 58.1% vs. 61.7%, respectively; *P* = 0.635) \[[Table 4](#T4){ref-type="table"}\].

###### 

Proportion of patients who required vasoactive drugs and incidence of adverse cardiovascular events

  Items                   Group A (*n* = 62) *n* (%)   Group B (*n* = 60) *n* (%)   *P*
  ----------------------- ---------------------------- ---------------------------- -------
  Vasoactive drugs                                                                  
   Atropine               3 (4.8)                      1 (1.7)                      0.635
   Esmolol                24 (38.7)                    17 (28.3)                    0.225
   Phenylephrine          52 (86.7)                    49 (81.7)                    0.747
   Urapidil               36 (58.1)                    37 (61.7)                    0.685
  Adverse                                                                           
  cardiovascular events                                                             
   Acute coronary         2 (3.2)                      1 (1.7)                      1.000
   syndrome                                                                         
   Arrhythmia             1 (1.6)                      0 (0)                        1.000

Adverse cardiovascular events {#sec2-7}
-----------------------------

Adverse cardiovascular events in the hospital were comparable between Groups A and B (4.8% vs. 1.7%; *P* = 0.619). New-onset angina was reported in two patients in Group A, and one in Group B. Frequent ventricular extrasystole was reported in one patient in Group A. There were no severe neurological complications during hospitalization \[[Table 4](#T4){ref-type="table"}\].

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

In our study, the incidence of myocardial injury, as detected by cTnI \>0.04 ng/ml, after CEA was lower in patients who received low-dose sevoflurane combined with propofol than in patients who received propofol alone. In-hospital adverse cardiovascular events did not significantly differ between the two groups. However, the relatively low incidence of myocardial injury in Group B showed that, in patients undergoing CEA, low-dose sevoflurane had a protective effect on the myocardium that extended to the first 3 postoperative days.

Our results are consistent with those of a previous study, in which the number of cardiac complications in CEA patients was significantly lower in those administered sevoflurane anesthesia than in those who received propofol.\[[@ref11]\]

Many studies have demonstrated the myocardial protective effect of sevoflurane in cardiac surgery, but its efficacy in noncardiac surgery is controversial. Some investigators found no difference between propofol and sevoflurane in myocardial protection in patients undergoing noncardiac surgery. A meta-analysis of 6219 noncardiac surgery patients from 79 randomized controlled studies was inconclusive. In that study, perioperative myocardial infarction and death served as the endpoints, but there were no cases of either one.\[[@ref19]\] However, myocardial infarction or ischemia may be clinically asymptomatic and thus evade detection unless more sensitive measure are used. Perioperative cTnI was shown to be sufficiently sensitive and specific to diagnose myocardial injury,\[[@ref20]\] and it is independent of ischemic symptoms.\[[@ref4]\] In their comparison of postoperative cTnI values in 88 noncardiac surgery patients, Zangrillo *et al.*\[[@ref21]\] found similar incidences of postoperative detectable cTnI and median peak cTnI values in the sevoflurane group versus the propofol group, but they did not identify the cut-off value of an abnormal cTnI or did they compare the incidence of myocardial injury.

In our study, the incidence of myocardial injury during the first 3 postoperative days was 29.0% in the propofol group, which was much lower than the 42.5% reported by Feng *et al.*,\[[@ref6]\] perhaps reflecting the different study protocols. Moreover, in that study,\[[@ref6]\] the patients were administered ephedrine to elevate blood pressure. Ephedrine is a noncatecholamine sympathomimetic agent that stimulates α- and β-adrenergic receptors both directly and indirectly. However, because it increases heart rate and myocardial oxygen consumption, its use is contraindicated for myocardial protection. In this study, we used phenylephrine, an α-agonist that causes reflex bradycardia in response to an increase in peripheral vascular resistance. Unlike ephedrine, phenylephrine confers myocardial protection. Another reason for the different incidences of myocardial injury in the two studies may have been the differences in patient age, since in the study by Feng *et al.*,\[[@ref6]\] 40% of the patients were older than 70 years of age compared to 29% in our study. Age ≥70 years was shown to be an independent risk factor for postoperative cardiac complications and mortality.\[[@ref22]\]

Mutch *et al.*\[[@ref23]\] reported that hemodynamic instability is associated with myocardial ischemia during CEA. In our patients, the MAP was maintained at 70--130% of the ward baseline value and heart rate at 50--100 bpm. Hemodynamic parameters did not significantly differ between the two groups and the doses of vasoactive drugs used both during the operation and during the first 3 postoperative days were comparable. Thus, differences in hemodynamics do not explain our findings.

This study had several limitations. First, we did not follow-up on the patients after hospital discharge. Several studies have shown that elevated cTnI values are associated with an increased frequency of delayed cardiac complications.\[[@ref17][@ref24]\] Whether low-dose sevoflurane leads to a medium- to long-term reduction in cardiac complications was not investigated in this study. Second, the samples sizes of the patients with different comorbid conditions were too small to obtain statistically relevant results. Third, because it was difficult to blind the anesthesiologists during the anesthetic procedure, this may have been a source of bias in this study.

Nonetheless, our results support the use of low-dose sevoflurane combined with propofol for anesthetic maintenance in symptomatic patients undergoing CEA. Compared to propofol alone, the two drugs significantly reduced the incidence of myocardial injury during the first 3 postoperative days after CEA.

**Edited by:** Li-Shao Guo

**Source of Support:** Nil.

**Conflict of Interest:** None declared.
